EA200100838A1 - Конъюгаты гксф - Google Patents

Конъюгаты гксф

Info

Publication number
EA200100838A1
EA200100838A1 EA200100838A EA200100838A EA200100838A1 EA 200100838 A1 EA200100838 A1 EA 200100838A1 EA 200100838 A EA200100838 A EA 200100838A EA 200100838 A EA200100838 A EA 200100838A EA 200100838 A1 EA200100838 A1 EA 200100838A1
Authority
EA
Eurasian Patent Office
Prior art keywords
conjugates
gksf
conjugate
mixture
formula
Prior art date
Application number
EA200100838A
Other languages
English (en)
Other versions
EA004685B1 (ru
Inventor
Паскаль Себастьян Байон
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of EA200100838A1 publication Critical patent/EA200100838A1/ru
Publication of EA004685B1 publication Critical patent/EA004685B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Описаны физиологически активные конъюгаты "ПЭГ-ГКСФ", имеющие формулу (I), а также композиции, содержащие смесь конъюгатов, где в каждом конъюгате данной композиции m и n могут представлять различные целые числа.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200100838A 1999-01-29 2000-01-19 Конъюгаты гксф EA004685B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11791799P 1999-01-29 1999-01-29
PCT/US2000/001264 WO2000044785A1 (en) 1999-01-29 2000-01-19 Gcsf conjugates

Publications (2)

Publication Number Publication Date
EA200100838A1 true EA200100838A1 (ru) 2002-04-25
EA004685B1 EA004685B1 (ru) 2004-06-24

Family

ID=22375505

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200400067A EA200400067A1 (ru) 1999-01-29 2000-01-19 Конъюгаты гксф
EA200100838A EA004685B1 (ru) 1999-01-29 2000-01-19 Конъюгаты гксф

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200400067A EA200400067A1 (ru) 1999-01-29 2000-01-19 Конъюгаты гксф

Country Status (26)

Country Link
US (4) US20030130193A1 (ru)
EP (1) EP1157037B1 (ru)
JP (1) JP2002540065A (ru)
KR (1) KR100689212B1 (ru)
CN (1) CN1376164A (ru)
AT (1) ATE246202T1 (ru)
AU (1) AU2618500A (ru)
BG (1) BG65213B1 (ru)
BR (1) BR0007781A (ru)
CA (1) CA2361766C (ru)
CZ (1) CZ300546B6 (ru)
DE (1) DE60004172T2 (ru)
DK (1) DK1157037T3 (ru)
EA (2) EA200400067A1 (ru)
ES (1) ES2204509T3 (ru)
HK (1) HK1049673A1 (ru)
HU (1) HU228488B1 (ru)
IL (1) IL144361A0 (ru)
MX (1) MXPA01007609A (ru)
NO (1) NO331787B1 (ru)
NZ (1) NZ513113A (ru)
PT (1) PT1157037E (ru)
RS (1) RS50928B (ru)
SK (1) SK286898B6 (ru)
WO (1) WO2000044785A1 (ru)
ZA (1) ZA200105932B (ru)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2204509T3 (es) * 1999-01-29 2004-05-01 F. Hoffmann-La Roche Ag Conjugados de gcsf.
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
AU2001290312A1 (en) 2000-10-16 2002-04-29 Chugai Seiyaku Kabushiki Kaisha Peg-modified erythropoietin
NZ532027A (en) * 2001-10-10 2008-09-26 Neose Technologies Inc Remodeling and glycoconjugation of peptides
CN105131104B (zh) * 2001-10-10 2018-11-16 诺和诺德公司 肽的重构和糖缀合
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
KR20070072924A (ko) * 2001-11-20 2007-07-06 파마시아 코포레이션 화학적으로 개질된 인간 성장 호르몬 콘쥬게이트
CA2492775C (en) 2002-07-24 2011-06-21 F. Hoffmann-La Roche Ag Polyalkylene glycol acid additives
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20070041937A1 (en) * 2003-08-22 2007-02-22 The Council Of The Queensland Institute Of Medical Research G-csf derivative for inducing immunological tolerance
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
ES2572779T3 (es) 2004-10-29 2016-06-02 Ratiopharm Gmbh Remodelación y glucopegilación del Factor de Crecimiento de Fibroblastos (FGF)
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
US20060174362A1 (en) * 2005-02-01 2006-08-03 Origen Therapeutics, Inc. Long-term culture of avian primordial germ cells (PGCs)
EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
BRPI0611221A2 (pt) 2005-06-01 2010-08-24 Maxygen Holdings Ltd polipeptÍdeos de g-csf peguilados e mÉtodos de produÇço dos mesmos
EP2279758B1 (en) 2005-06-16 2015-02-25 Nektar Therapeutics Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
JP2009503111A (ja) * 2005-08-04 2009-01-29 ネクター セラピューティックス エイエル，コーポレイション Ｇ−ｃｓｆ部分および重合体の複合体
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
JP2007112924A (ja) * 2005-10-21 2007-05-10 National Institute For Materials Science 高分子架橋剤及びこの架橋剤を用いたリポソーム又は細胞の架橋体
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
CN101002943B (zh) * 2006-01-17 2012-02-01 中国科学院过程工程研究所 支链peg-gcsf和peg-gmcsf结合物及其制备方法
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
ITMI20061624A1 (it) 2006-08-11 2008-02-12 Bioker Srl Mono-coniugati sito-specifici di g-csf
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES
WO2008051474A1 (en) * 2006-10-19 2008-05-02 The Uab Research Foundation Water soluble curcumin-based compounds
KR101079993B1 (ko) 2006-11-17 2011-11-04 동아제약주식회사 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
JP2008125952A (ja) * 2006-11-24 2008-06-05 National Institute For Materials Science 複合架橋体
CN101245109B (zh) * 2007-02-12 2011-12-14 杭州九源基因工程有限公司 一种聚乙二醇单修饰的重组人粒细胞集落刺激因子突变体及其制备方法
CA2682897C (en) 2007-04-03 2016-11-22 Biogenerix Ag Methods of treatment using glycopegylated g-csf
CN101778859B (zh) 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法
AR067537A1 (es) 2007-07-17 2009-10-14 Hoffmann La Roche Purificacion de polipeptidos pegilados
AR067536A1 (es) 2007-07-17 2009-10-14 Hoffmann La Roche Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
CN101352573B (zh) * 2007-07-27 2011-02-09 杭州九源基因工程有限公司 聚乙二醇单修饰的重组人集落细胞刺激因子赖氨酸缺陷体
US8629104B2 (en) 2008-02-18 2014-01-14 Jiangsu Hengrui Medicine Co. Ltd. G-CSF and water-soluble polymer conjugate
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
RU2409669C9 (ru) 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Способ иммобилизации биологически активного вещества (бав) на носитель (варианты) и конъюгат бав-носитель, полученный данными способами
JP5632376B2 (ja) 2008-09-23 2014-11-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ エリスロポエチンの精製
WO2011098400A1 (en) 2010-02-11 2011-08-18 F. Hoffmann-La Roche Ag Igf-i poly (ethylene glycol) conjugates
EP2616101B1 (en) 2010-09-14 2014-07-09 F.Hoffmann-La Roche Ag Method for purifying pegylated erythropoietin
US8889630B2 (en) 2011-12-23 2014-11-18 Carlos Lopez Method for hair regrowth using Granulocyte-Colony Stimulating Factor
CN109415427A (zh) 2016-07-15 2019-03-01 豪夫迈·罗氏有限公司 用于纯化聚乙二醇化的促红细胞生成素的方法
CN111565736B (zh) * 2017-10-11 2024-03-08 礼蓝美国股份有限公司 猪g-csf变体和其用途
KR102497097B1 (ko) 2017-12-29 2023-02-06 에프. 호프만-라 로슈 아게 페길화 단백질 조성물의 제공 방법
WO2019129877A1 (en) 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Process for providing pegylated protein composition
JP7137625B2 (ja) 2017-12-29 2022-09-14 エフ．ホフマン－ラ ロシュ アーゲー Ｐｅｇ化タンパク質組成物を提供するための方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1609546A (en) * 1925-11-19 1926-12-07 Petroleum Rectifying Co Process of separating water from emulsions
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4514497B1 (en) * 1983-12-30 1998-02-24 Novagene Inc Modified live pseudorabies viruses
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
US5532341A (en) * 1985-03-28 1996-07-02 Sloan-Kettering Institute For Cancer Research Human pluripotent hematopoietic colony stimulating factor
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US5194592A (en) * 1986-12-23 1993-03-16 Kyowa Hakko Kogyo Co. Ltd. Monoclonal antibodies to novel polypeptide derivatives of human granulocyte colony stimulating factor
US5362853A (en) * 1986-12-23 1994-11-08 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
DE68925966T2 (de) * 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3708151B2 (ja) * 1994-12-15 2005-10-19 協和醗酵工業株式会社 Ｐｅｇ化したヒト顆粒球コロニー刺激因子の定量法
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
KR0176625B1 (ko) * 1996-11-05 1999-04-01 삼성전자주식회사 적외선 물체검출장치
ES2204509T3 (es) * 1999-01-29 2004-05-01 F. Hoffmann-La Roche Ag Conjugados de gcsf.

Also Published As

Publication number Publication date
HK1049673A1 (zh) 2003-05-23
KR20020007296A (ko) 2002-01-26
EP1157037A1 (en) 2001-11-28
ZA200105932B (en) 2002-10-18
YU54301A (sh) 2003-10-31
PL363117A1 (en) 2004-11-15
US20080287659A1 (en) 2008-11-20
NO20013700L (no) 2001-09-25
CZ20012654A3 (cs) 2002-05-15
CN1376164A (zh) 2002-10-23
ATE246202T1 (de) 2003-08-15
NO20013700D0 (no) 2001-07-27
EA004685B1 (ru) 2004-06-24
CZ300546B6 (cs) 2009-06-10
PT1157037E (pt) 2003-12-31
NZ513113A (en) 2004-03-26
BR0007781A (pt) 2002-02-05
WO2000044785A1 (en) 2000-08-03
DE60004172D1 (de) 2003-09-04
BG65213B1 (bg) 2007-07-31
RS50928B (sr) 2010-08-31
HU228488B1 (en) 2013-03-28
CA2361766C (en) 2011-12-06
MXPA01007609A (es) 2003-06-24
ES2204509T3 (es) 2004-05-01
EP1157037B1 (en) 2003-07-30
NO331787B1 (no) 2012-04-02
HUP0203652A3 (en) 2005-01-28
AU2618500A (en) 2000-08-18
DK1157037T3 (da) 2003-11-24
BG105851A (en) 2002-06-28
SK286898B6 (sk) 2009-07-06
HUP0203652A2 (hu) 2003-03-28
US20030130193A1 (en) 2003-07-10
SK10352001A3 (sk) 2002-06-04
CA2361766A1 (en) 2000-08-03
US20070219356A1 (en) 2007-09-20
DE60004172T2 (de) 2004-04-22
JP2002540065A (ja) 2002-11-26
KR100689212B1 (ko) 2007-03-09
EA200400067A1 (ru) 2004-04-29
US20050196378A1 (en) 2005-09-08
IL144361A0 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
EA200400067A1 (ru) Конъюгаты гксф
EA200200938A1 (ru) Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение
TR199801179T2 (xx) Yeni taksoitler, bunlar�n haz�rlanmalar� ve ila� bile�imleri.
BR0111639A (pt) Uso de uma molécula de ácido oligodeoxinucléico, e composição farmacêutica contendo a mesma
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
EA200100139A1 (ru) Фармацевтические композиции, содержащие 2-хинолоны
SE9504661D0 (sv) New compounds
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
EA200300082A1 (ru) S-ФТОРМЕТИЛОВЫЙ ЭФИР 6α, 9α-ДИФТОР-17α-[(2-ФУРАНИЛКАРБОНИЛ)ОКСИ]-11β-ГИДРОКСИ-16α-МЕТИЛ-3-ОКСО-АНДРОСТА-1,4-ДИЕН-17β КАРБОТИОКИСЛОТЫ В КАЧЕСТВЕ ПРОТИВОВОСПАЛИТЕЛЬНОГО АГЕНТА
EA199900598A1 (ru) Производные 1-арил- и пиридилпиразола с пестицидными свойствами
EA200200479A1 (ru) Новые олигосахариды, их получение и содержащие их фармацевтические композиции
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
EA200200571A1 (ru) Новая композиция и ее применение
EA200100983A1 (ru) Производные 13-метилэритромицина
EA199800357A1 (ru) Фармацевтические ангиостатические дипептидные композиции и способы их применения
CY1112139T1 (el) Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης
EA200400708A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
BR1100143A (pt) Composto, e, composição farmacêutica.
ZA991546B (en) Streptogramin derivatives, their preparation and compositions containing them.
EA200100984A1 (ru) Новые кристаллические формы макролидного антибиотика
SE9504662D0 (sv) New compounds
PT912167E (pt) Granulos de derivados de hexa-hidropirazina administraveis por via oral
TR200002293T2 (tr) Farmasötik bileşimler.
EA200100269A1 (ru) Иммуногенные липосомные композиции
EA199700032A1 (ru) Дезинфицирующий состав "велтолен"

Legal Events

Date Code Title Description
MK4A Patent expired

Designated state(s): AM AZ BY KZ KG MD TJ TM RU